Quarter
Charts

MARIMED INC. — Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Cash-Flow Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-0
Book Value Per Share
$0
Free Cash Flow Per Share
$0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$0
Return on Equity
-26.7%
Return on Assets
-7.1%
Return on Invested Capital
-1.7%
Debt to Equity
1.52
Current Ratio
1.00
Quick Ratio
0.38
Asset Turnover
0.78
Days Sales Outstanding
20.81
Days Payables Outstanding
52.22
Days Inventory On Hand
131.04
Cash Conversion Cycle
99.64
R&D / Revenue
—
SBC / Revenue
1.2%
Capex / Revenue
0.7%
Working Capital
$223K
Net Current Asset Value
$-79M
Invested Capital
$126M
OCF / Net Income
-0.53
FCF / Net Income
-0.45
Accruals Ratio (Sloan)
-10.9%
Net Debt
$76M
Net Debt / EBITDA
14.38
Interest Coverage
-0.38
Cash Coverage
1.03
Capex Coverage
6.59
Tangible Common Equity
$9M
TCE / Total Assets
4.3%
Goodwill / Total Assets
11.8%
NOPAT
$-2M
Cash ROIC
5.0%
WC / Revenue
0.1%
Capex / D&A
0.14
Reinvestment Rate
254.4%
Asset Growth vs Revenue Growth
-3.5%
Revenue 5Y CAGR
25.7%
EBITDA 5Y CAGR
-20.2%
Book Value 5Y CAGR
43.9%
Stock Price (FY-end)
$0
Market Cap
$37M
P/E Ratio
—
P/S Ratio
0.23
P/B Ratio
0.73
P/TB Ratio
4.17
P/OCF Ratio
4.77
P/FCF Ratio
5.62
Enterprise Value
$113M
EV / EBITDA
21.31
EV / Sales
0.71
EV / FCF
17.27
FCF Yield
17.8%
Shareholder Yield
-5.1%
Capex Yield
3.2%
Operating Leverage
-13.35
Graham Number
—
Shares Variation (YoY)
2.9%
Beta (5Y)
0.45
Cost of Equity
6.7%
Cost of Debt (after tax)
7.8%
WACC
7.5%
ROIC - WACC Spread
-9.1%
52W High
$0
52W Low
$0
Trailing Return 1Y
-21.7%
Trailing Return 5Y
-74.6%
F-Score (Piotroski)
4.00
Z-Score (Altman)
0.02

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

MARIMED INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes46.00%16.50%12.80%-4.20%-9.90%-5.00%
Foreign Rate Differential——————
Other Adjustments-1.00%0.90%8.20%-1.20%3.40%-0.70%
Valuation Allowance Change-93.60%19.50%2.00%-96.90%67.10%23.30%
Effective Tax Rate46.00%63.30%28.60%-129.00%-1.91%-32.90%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$2.1M$16.2M$5.9M$9.4M$8.2M$3.6M
Income Taxes Paid (Cash)$1.2M$621.0K$14.6M$6.4M$705.0K−$713.0K